Mr. Schwarzer has served as our chief executive officer and a member of our board since 2010. Mr. Schwarzer also served as a managing partner of Charter Life Sciences, a venture capital firm specializing in life sciences investments, for approximately 15 years. He also served as the chair of Inviragen, the creators of the DENVax dengue vaccine, from the time of its first venture capital financing until its acquisition by Takeda. He previously served as chief executive officer and then chair of the board of directors of Heska Corporation, a biotechnology company. Mr. Schwarzer received a B.A. in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California, Berkeley, School of Law.
Dr. Keyt has served as our chief scientific officer since 2012, after serving in that role as a consultant for us beginning in 2010. Prior to joining us, Dr. Keyt served as chief technology officer at Trellis Bioscience, an antibody discovery company, from 2007 to 2010. Previously, he served as head of research for Abmaxis, a biotechnology company, from 2005 through its acquisition by Merck in 2006. He was also vice president of preclinical development at Abgenix, a biotechnology company, from 2001 through its acquisition by Amgen in 2005. Dr. Keyt was the director of pharmacology at Millennium Pharmaceuticals from 1998 to 2001. From 1982 to 1998, he served in various research and leadership roles at Roche/Genentech, where he made significant contributions to the discovery and development of Avastin, Lucentis, Activase tPA, TNKase-tPA and Kogenate (Factor VIII). Dr. Keyt received a B.A. in Chemistry from Washington University in St. Louis and a Ph.D. in Biochemistry and Pharmacology from Tufts University School of Medicine.
Dr. Chen has served as our chief medical officer since 2018. Dr. Chen joined us from Roche/Genentech, where he served in various research and leadership positions, most recently as vice president, global head of cancer immunotherapy since 2006. While at Roche/Genentech, he also served as cancer immunotherapy franchise head, product development and led the development of Tecentriq from entry into first in human studies to multiple global registration approvals. Dr. Chen also serves on the board of directors of the Society for Immunotherapy of Cancer and is co-chair of the Cancer Immunotherapy Committee, an arm of the Cancer Research Institute. Dr. Chen received a B.S. in Biology from the Massachusetts Institute of Technology and an M.D. and Ph.D. from the University of Southern California School of Medicine and Microbiology & Immunology. He completed his residency in internal medicine, a fellowship in Medical Oncology and a post doctorate in Immunology at Stanford University. Dr. Chen ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003 to 2006, where he also cared for melanoma patients and studied human immune responses to cancer vaccination and cytokine administration until 2016.
Mr. Tahir has served as our chief financial officer since 2019. Prior to joining us, Mr. Tahir worked at Dermira, a biotechnology company, where he served in various roles from 2014 to 2018, most recently, vice president, head of finance. Previously, he held finance and leadership positions at various biotechnology companies, including Onyx Pharmaceuticals, Human Genome Sciences and Amgen. Mr. Tahir began his career as a management consultant at the consulting firm of Oliver Wyman, formerly Mercer Management Consulting. He received a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from the University of Michigan Business School.
Dr. Baliga has served as our vice president, discovery biology since 2014. Prior to joining us, Dr. Baliga founded Extend Biopharma, a biotechnology company, and served as its chief science officer from 2012 until 2014. Previously, Dr. Baliga held scientific and leadership positions at Sutro Biopharma, Catalyst Biosciences and Cytokinetics. He received an M.Sc. in Organic Chemistry from the Indian Institute of Technology and a Ph.D. in Bio-organic Chemistry from the California Institute of Technology. Dr. Baliga also completed a post doctorate in Biophysics at Yale University.
Dr. Carroll has served as our vice president, preclinical sciences since 2015, after having served as a consultant for us beginning in 2013. Previously, Dr. Carroll spent 17 years in various scientific and leadership positions at Xoma, a biotechnology company, including vice president of preclinical research and scientific and product development. He received a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Microbiology from the University of California, Los Angeles. Dr. Carroll also completed a post doctorate in Microbiology at the University of California, Los Angeles, and he was an Assistant Professor in the Department of Microbiology and Molecular Genetics at Harvard Medical School.
Dr. Godfrey has served as our vice president, clinical development since 2018. Prior to joining us, Dr. Godfrey served as senior director, clinical development at Kite Pharma, a biotechnology company and subsidiary of Gilead, from 2017 to 2018. Dr. Godfrey also served as chief medical officer at Etubics, a biotechnology company, from 2015 to 2016, and as senior director, clinical research oncology at Gilead from 2012 to 2015. He received a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Barbara, an M.S. in Biology from Stanford University and an M.D. from Washington University School of Medicine in St. Louis. Dr. Godfrey completed his internal medicine residency and clinical immunology, hematology and bone marrow transplantation fellowships at Stanford University.
Dr. Peterson has served as our vice president, manufacturing and process sciences since 2017. Dr. Peterson also served as senior director, manufacturing at MabVax Therapeutics, a biotechnology company, from 2015 to 2017 and as senior director, upstream process development and manufacturing at Ambrx, a biotechnology company, from 2014 to 2015. Dr. Peterson has also served in manufacturing, scientific and leadership positions at Bristol-Myers Squibb, Eli Lilly, Celgene and Shire. He received a B.S. in Chemical Engineering from the University of Colorado, Boulder and a Ph.D. in Chemical Engineering from Purdue University. Dr. Peterson also completed a post doctorate at the University of Minnesota, BioProcess Technology Institute.
Dr. Sinclair has served as our vice president, immuno-oncology since 2018. Prior to joining us, Dr. Sinclair served as senior director, oncology research at Northern Biologics, a biotechnology company, from 2015 to 2018. He also previously served in various scientific and leadership positions at Amgen, including most recently as scientific director, oncology research, from 2011 to 2015. Dr. Sinclair received a B.Sc. in Molecular Biology from the University of Edinburgh and a Ph.D. in Hematology/Molecular Biology from the National Institute for Medical Research/University College London.
Ms. Tauber has served as our vice president of Human Resources since 2019. Prior to joining us, Ms. Tauber was in charge of human resources at ARMO BioSciences, a biotechnology company, from before its initial public offering through its acquisition by Eli Lilly. Previously, she held human resources leadership positions at a variety of life science and high-technology companies, including Cellular Research (acquired by Becton Dickinson), Kapor Enterprises, Escalate, KIVA Software (acquired by Netscape/AOL) and Bay Networks (acquired by Nortel). Ms. Tauber’s career in human resources began with Bain & Company, where she led their West Coast recruiting efforts. She received a B.A. in Communications from Northern Arizona University.